Author of

• 12544

  +

  P3.08 - Poster Session 3 - Radiotherapy (ID 199)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Radiation Oncology + Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12570

    +

    P3.08-026 - Factors Influencing One Year Survival in Radical Radiotherapy Treated Lung cancer Patients December 2010-November 2011, Beatson West Scotland Cancer Centre (ID 3120)

    09:30 - 09:30  |  Author(s): E. McCartney
    • Abstract

    Background
    Radical radiotherapy, with or without chemotherapy, is a treatment modality for early and late stage inoperable lung cancer. We investigated patients treated with curative intent over the course of one year.

    Methods
    Patients who received radical radiotherapy for lung cancer from Dec 2010 to Nov 2011 at the Beatson West of Scotland Cancer Centre were reviewed retrospectively. Information was gathered from the patient clinical records and the radiotherapy planning records (ARIA). All patients with lung cancer who received radical conventional radiotherapy (a total dose of 45- 66Gy) with or without sequential or concurrent chemotherapy were included. Patient demographics, disease characteristics, radiotherapy planning treatment parameters and overall survival were analysed using standard statistical methods.

    Results
    A total of 179 lung cancer patients received conventional radical radiotherapy. Median age 70 years, 55% were female, with ECOG 0 25%, ECOG 1 62%, ECOG 2 13%. Patients Deprivation Score as per Scottish Index of Multiple Deprivation score 2012: 44% are 1 (most deprived), 26% are 2, 13% are 3, 9 % are 4 and 8% are 5(least deprived). 22%(39/179) are stage I, 19%(34/179) stage II, 58%(104/179) stage III, and 0.6%(2/179) are stage IV. 51%(91/179) squamous cell carcinoma, 25%(44/179) adenocarcinoma, 7%(13/179) small cell carcinoma, 12%(22/179) had no histology and 5%(4/179) were neuroendocrine and others. 99% completed their prescribed radiotherapy. The mean whole lung V20 and whole lung V5 were 22.1% and 49.4% respectively. Mean PTV was 409.6 ml. 62/179(35%) died within the first year of receiving their radical radiotherapy. Out of those who died 33/62 PTV <500ml, 26/62 PTV 500-1000ml, 3/62 PTV>1000. 26/62 were treated with radiotherapy alone and 36/62 had received chemoradiotherapy. On univariate analysis using log-rank, age (p=0.663), sex (p=0.437), performance status (p=0.403), deprivation score (p=0.133), stage (p=0 .117), V20 (p=0.084) and V5 (p=0.064) were not significant factors affecting survival. PTV (p=0.020) and chemoradiotherapy (p=0.001) were statistically significant variable affecting survival. On multivariate analysis using Cox-regression PTV remained significant with respect to overall survival.

    Conclusion
    The outcome of this audit demonstrates that PTV is a significant variable affecting the survival of the patients in the first year after treatment. It was of interest to us that clinical stage, whole lung V20 and V5 were not significantly associated with survival. We also observed a significant one year survival difference in patients who were treated with radical radiotherapy alone compared with chemoradiotherapy. Overall survival was also not associated with deprivation score with survival outcomes similar across the whole population. The radiotherapy PTV may be an important variable when deciding treatment independent of other radiotherapy planning parameters.